Artivion, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.

Artivion, Inc. (NYSE: AORT) is a medical device company focused on cardiac and vascular surgery, particularly the treatment of aortic diseases. News about Artivion frequently centers on its aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as clinical and regulatory developments related to these products.

Investors and clinicians following AORT news can expect regular updates on quarterly financial results, including revenue trends for key product lines such as stent grafts, On-X valves, BioGlue surgical sealant and preservation services. Earnings releases often discuss constant currency growth, adjusted EBITDA and non-GAAP performance metrics, along with management’s commentary on business momentum and financial outlook.

Artivion’s news flow also highlights progress in its aortic disease clinical programs. Recent announcements have covered the PERSEVERE and PROTECT trials for the AMDS Hybrid Prosthesis, including late-breaking data presented at major cardiothoracic surgery meetings, as well as the ARTIZEN pivotal trial evaluating the Arcevo LSA Hybrid Stent Graft System for acute and chronic aortic arch pathologies. These updates provide insight into the clinical performance and potential regulatory pathways for the company’s aortic technologies.

Additional news items may include participation in healthcare and medtech investor conferences, amendments to credit facilities, real estate transactions related to manufacturing capacity, and executive leadership changes disclosed through SEC filings and press releases. For market participants tracking AORT, this news page offers a centralized view of Artivion’s financial communications, clinical milestones and corporate developments over time.